Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INDIANAPOLIS--(BUSINESS WIRE)--THE BOARD OF DIRECTORS OF ELEVANCE HEALTH (NYSE: ELV) ANNOUNCED TODAY THAT STEVE COLLIS, A HIGHLY REGARDED GLOBAL HEALTHCARE EXECUTIVE, WILL BE JOINING THE COMPANY'S BOARD, EFFECTIVE AUGUST 1. HE WILL ALSO SERVE ON THE BOARD'S AUDIT AND FINANCE COMMITTEES, FURTHER ENHANCING THE BOARD'S INDUSTRY EXPERTISE AND FINANCIAL OVERSIGHT CAPABILITIES. HIS ADDITION IS PART OF THE BOARD'S ONGOING COMMITMENT AND STRUCTURED APPROACH TO REFRESH ITS MEMBERSHIP IN SUPPORT OF THE C.

ELEVANCE HEALTH BOARD WELCOMES STEVE COLLIS AS NEW DIRECTOR, REFLECTING ONGOING COMMITMENT TO GOVERNANCE EXCELLENCE

INDIANAPOLIS--(BUSINESS WIRE)-- #DIGITALHEALTH--STUDY BY ELEVANCE HEALTH, UCI, IN COLLABORATION WITH APPLE, HIGHLIGHTS POTENTIAL OF DIGITAL HEALTH TOOLS TO REDUCE ASTHMA BURDEN IN U.S. POPULATIONS.

STUDY FINDS DIGITAL ASTHMA PROGRAM SIGNIFICANTLY IMPROVES SYMPTOM CONTROL IN ADULTS

INDIANAPOLIS--(BUSINESS WIRE)--ELEVANCE HEALTH, INC. (NYSE: ELV) REPORTED SECOND QUARTER 2025 RESULTS. "IN THE SECOND QUARTER, ELEVANCE HEALTH MADE MEANINGFUL PROGRESS IN DELIVERING AN EXPERIENCE THAT IS SIMPLE AND PERSONAL TO THOSE WE SERVE, WHILE ADVANCING OUR EFFORTS TO ENHANCE EFFICIENCY ACROSS THE HEALTHCARE SYSTEM. WE ARE UPDATING OUR OUTLOOK TO REFLECT ELEVATED MEDICAL COST TRENDS IN ACA AND SLOWER RATE ALIGNMENT IN MEDICAID. WHILE THE EXTERNAL ENVIRONMENT CONTINUES TO EVOLVE, WE ARE FOC.

ELEVANCE HEALTH REPORTS SECOND QUARTER 2025 RESULTS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ELEVANCE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ELEVANCE HEALTH

PHILADELPHIA , JULY 10, 2025 /PRNEWSWIRE/ -- BERGER MONTAGUE PC ADVISES INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. ("ELEVANCE" OR THE "COMPANY") (NYSE: ELV) ON BEHALF OF PURCHASERS OF ELEVANCESECURITIES BETWEENAPRIL 18, 2024 THROUGH OCTOBER 16, 2024,INCLUSIVE (THE "CLASS PERIOD"). INVESTOR DEADLINE: INVESTORS WHO PURCHASED OR ACQUIRED ELEVANCE SECURITIES DURING THE CLASS PERIOD MAY, NO LATER THAN JULY 11, 2025 , SEEK TO BE APPOINTED AS A LEAD PLAINTIFF REPRESENTATIVE OF THE CLASS.

DEADLINE TOMORROW: BERGER MONTAGUE ADVISES ELEVANCE HEALTH (NYSE: ELV) INVESTORS TO CONTACT THE FIRM BEFORE JULY 11, 2025

NEW YORK, JULY 10, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. (NYSE: ELV) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ELEVANCE YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING HTTPS://WWW.BFALAW.COM/CASES-INVESTIGATIONS/ELEVANCE-HEALTH-INC.

ELV COURT NOTICE: ELEVANCE HEALTH, INC. INVESTORS MAY HAVE BEEN AFFECTED BY FRAUD  CONTACT BFA LAW BY THE JULY 11 LEGAL DEADLINE (NYSE:ELV)

INVESTORS CAN CONTACT THE LAW FIRM AT NO COST TO LEARN MORE ABOUT RECOVERING THEIR LOSSES

ELEVANCE HEALTH, INC. INVESTORS: PLEASE CONTACT THE PORTNOY LAW FIRM TO RECOVER YOUR LOSSES. JULY 11, 2025 DEADLINE TO FILE LEAD PLAINTIFF MOTION.

PHILADELPHIA , JULY 7, 2025 /PRNEWSWIRE/ -- BERGER MONTAGUE PC ADVISES INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. ("ELEVANCE" OR THE "COMPANY") (NYSE: ELV) ON BEHALF OF PURCHASERS OF ELEVANCESECURITIES BETWEENAPRIL 18, 2024 THROUGH OCTOBER 16, 2024,INCLUSIVE (THE "CLASS PERIOD"). INVESTOR DEADLINE: INVESTORS WHO PURCHASED OR ACQUIRED ELEVANCE SECURITIES DURING THE CLASS PERIOD MAY, NO LATER THAN JULY 11, 2025 , SEEK TO BE APPOINTED AS A LEAD PLAINTIFF REPRESENTATIVE OF THE CLASS.

DEADLINE THIS WEEK: BERGER MONTAGUE ADVISES ELEVANCE HEALTH (NYSE: ELV) INVESTORS TO CONTACT THE FIRM BEFORE JULY 11, 2025

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN ELEVANCE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ELEVANCE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ELEVANCE BETWEEN APRIL 18, 2024 AND OCTOBER 16, 2024 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , JULY 3, 2025 /PRNEWSWIRE/ --FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ELEVANCE HEALTH, INC. ("ELEVANCE" OR THE "COMPANY") (NYSE: ELV) AND REMINDS INVESTORS OF THE JULY 11, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ELEVANCE HEALTH

INDIANAPOLIS--(BUSINESS WIRE)--ELEVANCE HEALTH (NYSE: ELV) WILL RELEASE SECOND QUARTER 2025 FINANCIAL RESULTS ON JULY 17, 2025, AT 6:00 A.M. EASTERN DAYLIGHT TIME (EDT). MANAGEMENT WILL REVIEW THESE RESULTS AND ITS OUTLOOK DURING A CONFERENCE CALL AT 8:30 A.M. EDT THAT SAME MORNING. THE CONFERENCE CALL SHOULD BE ACCESSED AT LEAST 15 MINUTES PRIOR TO ITS START WITH THE FOLLOWING NUMBERS: 888-947-9963 - ACCESS CODE - 3972058 (DOMESTIC) 312-470-0178 - ACCESS CODE - 3972058 (INTERNATIONAL) 866-51.

ELEVANCE HEALTH TO HOLD CONFERENCE CALL AND WEBCAST TO DISCUSS SECOND QUARTER 2025 RESULTS ON JULY 17

DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ELEVANCE HEALTH

NEW YORK--(BUSINESS WIRE)--ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS INVESTORS THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF COMMON STOCK OF ELEVANCE HEALTH, INC. (NYSE: ELV) BETWEEN APRIL 18, 2024, AND OCTOBER 16, 2024. ELEVANCE DESCRIBES ITSELF AS A HEALTHCARE COMPANY THAT PROVIDES HEALTH INSURANCE PLANS TO A VARIETY OF MARKETS. FOR MORE INFORMATION, SUBMIT A FORM, EMAIL ATTORNEY PHILLIP KIM, OR GIVE US A CALL AT 866-767-3653. THE ALLEGATIONS: ROSEN LAW.

ELV DEADLINE: ROSEN LAW FIRM URGES ELEVANCE HEALTH, INC. (NYSE: ELV) STOCKHOLDERS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK, JUNE 28, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. (NYSE: ELV) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ELEVANCE YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING HTTPS://WWW.BFALAW.COM/CASES-INVESTIGATIONS/ELEVANCE-HEALTH-INC.

ELV INVESTOR DEADLINE: ELEVANCE HEALTH, INC. INVESTORS WITH LOSSES MAY HAVE BEEN AFFECTED BY FRAUD  CONTACT BFA LAW BY JULY 11 COURT DEADLINE (NYSE:ELV)

INDIANAPOLIS--(BUSINESS WIRE)--ELEVANCE HEALTH FOUNDATION RECENTLY ANNOUNCED A $1.5 MILLION GRANT TO HEALTHCONNECT ONE, AN ORGANIZATION COMMITTED TO EXPANDING COMMUNITY-BASED DOULA CARE AND ADDRESSING MATERNAL HEALTH DISPARITIES. WITH THIS GRANT, HEALTHCONNECT ONE WILL LAUNCH NEW DOULA TRAINING PROGRAMS WITH COMMUNITY-BASED ORGANIZATIONS IN CALIFORNIA, GEORGIA, INDIANA, OHIO, NEW YORK, AND VIRGINIA. MATERNAL AND CHILD HEALTH CHALLENGES PERSIST ACROSS THE COUNTRY, INCLUDING HIGH PRE-TERM BIRTH R.

ELEVANCE HEALTH FOUNDATION INVESTS $1.5 MILLION TO ACCELERATE DOULA TRAINING WITH HEALTHCONNECT ONE

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ELEVANCE HEALTH

NEW YORK, JUNE 20, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. (NYSE: ELV) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ELEVANCE YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING HTTPS://WWW.BFALAW.COM/CASES-INVESTIGATIONS/ELEVANCE-HEALTH-INC.

ELV COURT REMINDER: ELEVANCE HEALTH, INC. INVESTORS THAT LOST MONEY MAY HAVE BEEN AFFECTED BY FRAUD -- CONTACT BFA LAW BY JULY 11 COURT DEADLINE (NYSE:ELV)

NEW YORK, JUNE 18, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. (NYSE: ELV) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ELEVANCE YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING HTTPS://WWW.BFALAW.COM/CASES-INVESTIGATIONS/ELEVANCE-HEALTH-INC.

ELV NOTICE: DID ELEVANCE HEALTH, INC. MISLEAD INVESTORS? CONTACT BFA LAW BY JULY 11 COURT DEADLINE IF YOU SUFFERED LOSSES (NYSE:ELV)

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN ELEVANCE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $100,000 IN ELEVANCE BETWEEN APRIL 18, 2024 AND OCTOBER 16, 2024 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK, JUNE 18, 2025 (GLOBE NEWSWIRE) -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ELEVANCE HEALTH, INC. (ELEVANCE OR THE COMPANY) (NYSE: ELV) AND REMINDS INVESTORS OF THE JULY 11, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK, JUNE 16, 2025 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES THAT A LAWSUIT HAS BEEN FILED AGAINST ELEVANCE HEALTH, INC. (NYSE: ELV) AND CERTAIN OF THE COMPANY'S SENIOR EXECUTIVES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ELEVANCE YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING HTTPS://WWW.BFALAW.COM/CASES-INVESTIGATIONS/ELEVANCE-HEALTH-INC.

ELV SHAREHOLDER REPORT: ELEVANCE HEALTH, INC. WAS SUED FOR FRAUD  INVESTORS WITH LOSSES ARE NOTIFIED TO CONTACT BFA LAW BY JULY 11 COURT DEADLINE (NYSE:ELV)

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $100,000 IN ELEVANCE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $100,000 IN ELEVANCE BETWEEN APRIL 18, 2024 AND OCTOBER 16, 2024 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , JUNE 15, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ELEVANCE HEALTH, INC. ("ELEVANCE" OR THE "COMPANY") (NYSE: ELV) AND REMINDS INVESTORS OF THE JULY 11, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

Elevance Health Inc.

ELV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Elevance Health Inc.

ELV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ELV